REGENXBIO Inc. (NASDAQ:RGNX) Shares Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 13.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 151,715 shares of the biotechnology company’s stock after purchasing an additional 17,525 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in REGENXBIO were worth $1,591,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in REGENXBIO by 80.3% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 170,218 shares of the biotechnology company’s stock worth $3,586,000 after buying an additional 75,800 shares during the last quarter. Integral Health Asset Management LLC lifted its stake in REGENXBIO by 25.0% during the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock worth $11,115,000 after purchasing an additional 190,000 shares during the last quarter. Quest Partners LLC boosted its holdings in REGENXBIO by 11,731.0% in the second quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company’s stock valued at $491,000 after purchasing an additional 41,645 shares in the last quarter. ProShare Advisors LLC increased its stake in REGENXBIO by 8.3% in the first quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock valued at $240,000 after purchasing an additional 874 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in REGENXBIO by 630.9% during the second quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company’s stock worth $1,711,000 after purchasing an additional 126,249 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

Analyst Ratings Changes

RGNX has been the subject of several research analyst reports. Raymond James restated an “outperform” rating and issued a $18.00 target price on shares of REGENXBIO in a report on Thursday, October 10th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Barclays reduced their target price on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, August 5th. HC Wainwright restated a “buy” rating and set a $39.00 price target on shares of REGENXBIO in a research note on Wednesday, September 4th. Finally, Chardan Capital reiterated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Tuesday, October 22nd. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, REGENXBIO has an average rating of “Moderate Buy” and a consensus target price of $35.45.

REGENXBIO Price Performance

NASDAQ:RGNX opened at $9.35 on Friday. The firm has a market cap of $460.54 million, a price-to-earnings ratio of -1.59 and a beta of 1.21. The firm’s fifty day moving average price is $11.10 and its 200 day moving average price is $13.01. REGENXBIO Inc. has a 1-year low of $9.11 and a 1-year high of $28.80.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The business had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.97 million. During the same quarter in the previous year, the firm earned ($1.66) earnings per share. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. As a group, analysts expect that REGENXBIO Inc. will post -4.66 earnings per share for the current fiscal year.

Insider Buying and Selling at REGENXBIO

In other news, CEO Curran Simpson sold 9,648 shares of the stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $15.04, for a total transaction of $145,105.92. Following the completion of the transaction, the chief executive officer now directly owns 170,137 shares of the company’s stock, valued at approximately $2,558,860.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Curran Simpson sold 9,648 shares of the company’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $15.04, for a total transaction of $145,105.92. Following the transaction, the chief executive officer now directly owns 170,137 shares of the company’s stock, valued at $2,558,860.48. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Argeris N. Karabelas sold 10,100 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $13.51, for a total transaction of $136,451.00. Following the completion of the transaction, the director now owns 11,286 shares of the company’s stock, valued at $152,473.86. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,848 shares of company stock valued at $665,197. 13.13% of the stock is owned by corporate insiders.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.